2016•Clinical Lymphoma Myeloma & LeukemiaRequires access

Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib

Andrew Kuykendall, Najla Al Ali, Chetasi Talati, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ruxolitinib, Myelofibrosis, Medicine, Internal medicine, Clinical trial, Oncology, Bone marrow

Back to paper search Browse research topics Original source

Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib — Research Paper | ScholarLens